Search

183 Result(s)
Sort by

What we do

What we do

Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Boehringer Ingelheim Access to Healthcare Strategy 2025

Boehringer Ingelheim Access to Healthcare Strategy 2025

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach.
Living Independence

Living Independence

Boehringer Ingelheim’s corporate culture is based on values that have been applied since the company was founded in 1885.
Vaccine bluetongue virus serotype 3 sheep cattle

Vaccine bluetongue virus serotype 3 sheep cattle

BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first BTV-3 vaccine that prevents clinical signs and mortality.
Fredrik Gruenenfelder

Fredrik Gruenenfelder

, Lead Risk Management Physician, talks about his career journey, from veterinarian to playing a key role in keeping patients safe.
opening-solids-launch-fabrik

opening-solids-launch-fabrik

Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.
Questions and Answers

Questions and Answers

Answers to common questions from both patients and health care professionals regarding Compassionate Use of experimental medications.